Back to Agenda
Predicting Drug Off-Target Protein Binding to Hypothesize Mechanisms for Safety Issues
Session Chair(s)
Keith K. Burkhart, MD
Senior Advisor for Medical Toxicology, DARS, OCP, OTS, FDA, United States
A new technology predicts a drug’s binding to protein ligands, potentially identifying off-target actions. Preclinical case studies and a postmarket analysis of drug-induced serotonin syndrome are presented.
Learning Objective : Discuss new technology that predicts off-target drug-protein binding; Describe applications for use throughout a drug’s life cycle; Demonstrate a biological plausibility analysis for serotonin syndrome.
Speaker(s)
Laszlo A. Urban, DRSC, MD, PHD
Global Head, Preclinical Safety Profiling, Novartis Institutes for BioMedical Research, Inc., United States
Use of In Silico Approach for Safety Assessment of Clinical Candidates: Mitigation and Management for Clinical Drug Positioning
Michael J. Keiser, PHD
Assistant Professor, UCSF; Founder, Seachange Pharmaceuticals Inc, United States
Predicting Secondary Pharmacology from Drug Off-Target Networks
Keith K. Burkhart, MD
Senior Advisor for Medical Toxicology, DARS, OCP, OTS, FDA, United States
Use of In Silico Protein Binding Predictions in Postmarket Safety Signal Analysis and Biological Plausibility
Have an account?